BioInvent International AB (publ) (BINV.ST)
SEK 39.75
(2.45%)
SEK 39.75
(2.45%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 23.24 Million SEK | -13.79% |
| 2022 | 26.96 Million SEK | -4.95% |
| 2021 | 28.36 Million SEK | 144.46% |
| 2020 | 11.6 Million SEK | -25.28% |
| 2019 | 15.52 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| 2007 | - SEK | 0.0% |
| 2006 | - SEK | 0.0% |
| 2005 | - SEK | 0.0% |
| 2004 | - SEK | 0.0% |
| 2003 | - SEK | 0.0% |
| 2002 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 19.11 Million SEK | -9.79% |
| 2024 Q1 | 21.18 Million SEK | -8.86% |
| 2024 Q3 | 8.7 Million SEK | -10.92% |
| 2023 Q4 | 23.24 Million SEK | 9.65% |
| 2023 Q3 | 21.19 Million SEK | -8.36% |
| 2023 FY | 23.24 Million SEK | -13.79% |
| 2023 Q2 | 23.13 Million SEK | -7.67% |
| 2023 Q1 | 25.05 Million SEK | -7.08% |
| 2022 Q1 | 26.78 Million SEK | -5.59% |
| 2022 Q3 | 23.57 Million SEK | -6.38% |
| 2022 Q4 | 26.96 Million SEK | 14.35% |
| 2022 FY | 26.96 Million SEK | -4.95% |
| 2022 Q2 | 25.18 Million SEK | -5.96% |
| 2021 Q4 | 28.36 Million SEK | -5.26% |
| 2021 FY | 28.36 Million SEK | 144.46% |
| 2021 Q1 | 10.16 Million SEK | -12.38% |
| 2021 Q3 | 29.94 Million SEK | -4.39% |
| 2021 Q2 | 31.31 Million SEK | 208.01% |
| 2020 Q1 | 14.08 Million SEK | -9.29% |
| 2020 FY | 11.6 Million SEK | -25.28% |
| 2020 Q4 | 11.6 Million SEK | 3.83% |
| 2020 Q3 | 11.17 Million SEK | -11.55% |
| 2020 Q2 | 12.63 Million SEK | -10.3% |
| 2019 Q3 | 16.96 Million SEK | -7.74% |
| 2019 Q4 | 15.52 Million SEK | -8.45% |
| 2019 FY | 15.52 Million SEK | 0.0% |
| 2019 Q1 | 19.8 Million SEK | 0.0% |
| 2019 Q2 | 18.38 Million SEK | -7.15% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2010 Q1 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q3 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2009 Q4 | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| 2007 FY | - SEK | 0.0% |
| 2006 FY | - SEK | 0.0% |
| 2005 FY | - SEK | 0.0% |
| 2004 FY | - SEK | 0.0% |
| 2003 FY | - SEK | 0.0% |
| 2002 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -44.4% |
| Ziccum AB (publ) | 857 Thousand SEK | -2612.252% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -366.841% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | 5.08% |
| Genovis AB (publ.) | 79.32 Million SEK | 70.696% |
| Intervacc AB (publ) | 181 Thousand SEK | -12741.989% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -12.775% |
| Active Biotech AB (publ) | 3 Million SEK | -674.8% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | 61.454% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -364.88% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 67.449% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -196.934% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -5382.075% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 78.597% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -657.134% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -800.93% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -2224.4% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 97.626% |
| Camurus AB (publ) | 24.5 Million SEK | 5.154% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | 15.679% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 97.318% |
| Cyxone AB (publ) | 858 Thousand SEK | -2609.091% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -1258.504% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | 36.851% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -3390.09% |
| SynAct Pharma AB | 637 Thousand SEK | -3548.98% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -2634.588% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -1219.932% |
| Alzinova AB (publ) | 800 Thousand SEK | -2805.5% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 78.172% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -2906.675% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 74.384% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | 24.218% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 89.958% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -2090.763% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |